Deuterated derivatives of ruxolitinib
The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.
1. A compound of Formula A:
or a pharmaceutically acceptable salt thereof, wherein:
Y 1 is hydrogen;
each Y 2 is selected from hydrogen and deuterium, and each Y 2 is the same;
each Y 3 is selected from hydrogen and deuterium, and each Y 3 is the same;
Y 4 is selected from hydrogen and deuterium;
each Y 5 is the same and is selected from hydrogen and deuterium; and
Y 6 , Y 7 , Y 8 , Y 9 and Y 10 are each independently selected from hydrogen and deuterium; provided that:
each Y 2 is deuterium; or
each Y 3 is deuterium; or
each Y 2 and each Y 3 is deuterium.
2. The compound of claim 1 , in which Y 4 is hydrogen and each Y 5 is hydrogen.
3. The compound of claim 1 , in which each Y 2 is deuterium and each Y 3 is hydrogen.
4. The compound of claim 1 , in which each Y 2 is hydrogen and each Y 3 is deuterium.
5. The compound of claim 1 , in which each Y 2 is deuterium and each Y 3 is deuterium.
6. The compound of claim 1 , in which Y 6 , Y 7 and Y 8 are each hydrogen.
7. The compound of claim 1 , in which the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt of any of the foregoing.
8. A pharmaceutical composition comprising the compound of claim 1 , and a pharmaceutically acceptable carrier.
9. A compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
Y 1 is hydrogen;
each Y 2 is selected from hydrogen and deuterium, and each Y 2 is the same;
each Y 3 is selected from hydrogen and deuterium, and each Y 3 is the same;
Y 4 is selected from hydrogen and deuterium;
each Y 5 is the same and is selected from hydrogen and deuterium; and
Y 6 , Y 7 and Y 8 are each independently selected from hydrogen and deuterium; provided that:
each Y 2 is deuterium; or
each Y 3 is deuterium; or
each Y 2 and each Y 3 is deuterium.
10. The compound of claim 9 , in which Y 4 is hydrogen and each Y 5 is hydrogen.
11. The compound of claim 9 , in which each Y 2 is deuterium and each Y 3 is hydrogen.
12. The compound of claim 9 , in which each Y 2 is hydrogen and each Y 3 is deuterium.
13. The compound of claim 9 , in which each Y 2 is deuterium and each Y 3 is deuterium.
14. The compound of claim 9 , in which Y 6 , Y 7 and Y 8 are each hydrogen.
15. A pharmaceutical composition comprising the compound of claim 9 , and a pharmaceutically acceptable carrier.